drugset / Trial / NCT00642746
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
Phase 2
Terminated
16 enrolled
OHSU Knight Cancer Institute
Genentech, Inc. · collabOSI Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to see if alternating chemotherapy with erlotinib increases tumor shrinkage in people with metastatic colorectal cancer. The investigator will also be studying the side effects (good and bad) of alternating chemotherapy with erlotinib on metastatic colorectal cancer.
Timeline
- Start
- 2008-03
- Primary completion
- 2011-12
- Completion
- 2011-12
Outcome
Outcome not reported
Stopped (Enrollment): “Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | — | Oral |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |